Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Protocol ID
CDRB436G2201
Disease (Sub Disease)
Low grade glioma
High grade glioma
High grade glioma
Diagnosis Stage
Relapse/refractory
Sponsor
Novartis Pharmaceuticals
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 2
Age Eligibility
12 Months to 17 Years
International registry ID's
NCT02684058
| Study Title | Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG) |
|---|---|
| Protocol ID | CDRB436G2201 |
| Disease (Sub Disease) | Low grade glioma High grade glioma |
| Diagnosis Stage | Relapse/refractory |
| Sponsor | Novartis Pharmaceuticals |
| Links | https://clinicaltrials.gov/ct2/show/NCT02684058 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 24/10/2017 |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 12 Months to 17 Years |
| International registry ID's | NCT02684058 |